

**A DECLARATION OF JOINT WORKING BETWEEN BRIDLINGTON PRIMARY CARE NETWORK AND  
ASTRAZENCA UK LTD**

Astra Zeneca and Bridlington Primary Care Network have entered into a Joint working agreement “The Bridlington CKD Project”.

This project is commissioned to begin 1<sup>st</sup> Jan 2022 to 1<sup>st</sup> May 2022

The project will:

- Develop and create a Pathway for CKD in Primary care.
- Developing a working pathway using NICE and KDIGO guidance with the input of secondary and primary care in the area.
- At the end of the project this Pathway will be reviewed to ensure it meets the local needs and is robust enough to deliver the desired behaviours and outcomes.

Robust Code cleansing and case finding to identify suitable patients for CKD Register to optimise QOF.

- A code cleansing review will be completed capturing all patients who have had eGFR, Urine tests, Blood tests or imagery tests to indicate CKD.
- Case Findings will include all Patients who have Diabetes and Heart Failure and those with a family history of CKD.

Review and optimise all identified patients who need, lifestyle change counselling, medication review to prevent progression of the disease and enhance patient outcomes.

- All identified patients will be categorised into recoding those patients who are incorrectly coded and must be added to QOF Register and flag on patient’s notes to assess the progression of the disease using eGFR.
- Review and optimisation of medication and care. This will be conducted by an ICS Grade 8 Pharmacist which will be contracted by the PCN.
- Appropriate lifestyle advice counselling by Dietician or other trained HCPs in Practice.
- Medicine review by an ICS Pharmacist working within the practice.
- NHS-led Imbedding learnings with a site meeting with all prescribing HCPs to ensure a legacy of patient care
- A Training and Review meeting will be held at the end of the project to review
- This day will be led by a Local Consultant and will involve the Pharmacist who delivered the Pilot, learnings and discuss best practices for all HCPs in the Practice.

Additionally:

The Pathway will be reviewed considering the project to ensure the pathway drives appropriate behaviours and Outcomes.

It is anticipated the project will be written up as a case study to support PCN 'DES' with a ready-made project to improve patient care at a PCN and Cluster Level. The writing of this case study will be undertaken by Astra Zeneca.

The project will run from January 1<sup>st</sup> 2022 to May 1st 2022. Both parties have contributed resources to the initiative.